Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Liabilities and Shareholders Equity: 2013-2018

Historic Liabilities and Shareholders Equity for Soleno Therapeutics (SLNO) over the last 6 years, with Dec 2018 value amounting to $43.2 million.

  • Soleno Therapeutics' Liabilities and Shareholders Equity fell 6.84% to $28.7 million in Q3 2019 from the same period last year, while for Sep 2019 it was $144.9 million, marking a year-over-year increase of 3.83%. This contributed to the annual value of $43.2 million for FY2018, which is 10.58% up from last year.
  • According to the latest figures from FY2018, Soleno Therapeutics' Liabilities and Shareholders Equity is $43.2 million, which was up 10.58% from $39.0 million recorded in FY2017.
  • Soleno Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $43.2 million for FY2018, and its period low was $5.6 million during FY2016.
  • For the 3-year period, Soleno Therapeutics' Liabilities and Shareholders Equity averaged around $29.2 million, with its median value being $39.0 million (2017).
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first slumped by 32.15% in 2016, then surged by 601.22% in 2017.
  • Yearly analysis of 5 years shows Soleno Therapeutics' Liabilities and Shareholders Equity stood at $8.4 million in 2014, then fell by 2.32% to $8.2 million in 2015, then plummeted by 32.15% to $5.6 million in 2016, then skyrocketed by 601.22% to $39.0 million in 2017, then increased by 10.58% to $43.2 million in 2018.